Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy

Giorgia Simonetti, Maria Teresa Sabrina Bertilaccio, Paolo Ghia, Ulf Klein

Research output: Contribution to journalArticlepeer-review

Abstract

Mouse models that recapitulate human malignancy are valuable tools for the elucidationof the underlying pathogenetic mechanisms and for preclinical studies. Several genetically engineered mousemodels have been generated, either mimicking genetic aberrations or deregulated gene expression in chronic lymphocytic leukemia (CLL). The usefulness of such models in the study of the human disease may potentially be hampered by species-specific biological differences in the target cell of the oncogenic transformation. Specifically, do the genetic lesions or the deregulated expression of leukemia-associated genes faithfully recapitulate the spectrum of lymphoproliferations in humans? Do the CLL-like lymphoproliferations in the mouse have the phenotypic, histological, genetic, and clinical features of the human disease? Here we compare the various CLL mouse models with regard to disease phenotype, penetrance, and severity. We discuss similarities and differences of the murine lymphoproliferations compared with human CLL. We propose that the Eμ-TCL1 transgenic and 13q14 -deletion models that have been comprehensively studied at the levels of leukemia phenotype, antigen-receptor repertoire, and disease courses how close resemblance to the human disease. We conclude that modeling CLL-associated genetic dysregulations in mice can provide important insights into the molecular mechanisms of disease pathogenesis and generate valuable tools for the development of novel therapies.

Original languageEnglish
Pages (from-to)1010-1019
Number of pages10
JournalBlood
Volume124
Issue number7
DOIs
Publication statusPublished - Aug 14 2014

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy'. Together they form a unique fingerprint.

Cite this